M 201-A - Aetas Pharma
Alternative Names: M-201-A; M201-A hydrochlorideLatest Information Update: 08 Dec 2022
At a glance
- Originator Aetas Pharma
- Developer Aetas Pharma; Kitasato University
- Class Antiarrhythmics
- Mechanism of Action Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Paroxysmal atrial fibrillation
Most Recent Events
- 08 Dec 2022 M 201-A is still in phase II trials for Paroxysmal atrial fibrillation in Japan (Aetas Pharma pipeline, December 2022)
- 30 Nov 2020 Kitasato University and Aetas Pharma completes a phase I pharmacokinetics trial in healthy volunteers in Japan (NCT04464681)
- 09 Jul 2020 Phase-I development is ongoing in Japan (NCT04464681)